BioCentury
ARTICLE | Clinical News

IV ANAVEX 2-73: Interim Phase IIa data

July 27, 2015 7:00 AM UTC

Interim data from 12 patients with mild to moderate AD in Part A of an open-label, crossover, Australian Phase IIa trial showed that ANAVEX 2-73 led to positive cognitive effects, as measured by the ...